Update 05/13/2021 (NASDAQ: RELI) our April 19th, 2021 report at $3.10/share announced an acquisition today and has broken above the 50DMA crossing $4....
Three Reports Over 215% in Bookable Gains to Cap off 2020 for our Members, New Report on Deck
2020 was an amazing year for our group! Well over 2500% in realistic bookable gains. We will be kicking off 2021 with our first feature report Tuesda...
Genprex (NASDAQ: GNPX) Completes Another Milestone
We believe GNPX has just gotten started. Their ONCOPREX delivery system and the REQORSA technology are proprietary and no one else has anything like i...
These “Tiny Bubbles” from Genprex (GNPX) Could Beat Cancer
The FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of non-small cell lung cancer.